Therapeutic opportunities in vasoocclusive disease.
There is evidence that aspirin is partially effective in the prophylaxis of various vasoocclusive disorders. This article reviews pharmacologic opportunities for improvement over and above the therapeutic effect of aspirin. It is concluded that several rational possibilities merit consideration, in particular, the use of combinations of drugs that affect the thrombotic process at different points. Such strategies will ultimately require validation by clinical trial.
D001157:Arterial Occlusive Diseases / Q000517:prevention & control*; D001792:Blood Platelets / Q000187:drug effects*; D016861:Cyclooxygenase Inhibitors; D011464:Epoprostenol / Q000627:therapeutic use; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011457:Prostaglandins D / Q000627:therapeutic use; D011982:Receptors, Prostaglandin / Q000187:drug effects; D017482:Receptors, Thromboxane; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors
D016861:Cyclooxygenase Inhibitors; D010726:Phosphodiesterase Inhibitors; D011457:Prostaglandins D; D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D011464:Epoprostenol; D013930:Thromboxane-A Synthase